| LY3009104 |
| 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile |
| (CAS 1187594-09-7) |
 |
| Description： |
Janus kinases (JAKs) are non-receptor kinases that mediate signaling through cytokine receptors, often to members of the signal transducer and activator of transcription (Stat) family. Baricitinib is an orally bioavailable, reversible inhibitor of JAK1 and JAK2 (IC50s = 5.9 and 5.7 nM, respectively) that has been shown to inhibit cytokine-induced phosphorylation of STAT3 in healthy human volunteers. It has potential application in various inflammatory disorders, including rheumatoid arthritis.
|
| Product No. |
KT00532 |
| Product Name |
LY3009104 |
| Synonyms |
INCB 028050,LY3009104 |
| Formal Name |
1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile |
| CAS Number |
1187594-09-7 |
| Molecular Formula |
C16H17N7O2S |
| Formula Weight |
371.4 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
(3R,4S)-Tofacitinib
(3S,4R)-Tofacitinib
(3S,4S)-Tofacitinib
AG-490
AT9283
AZD-1480
BMS-911543
CEP-33779
CYT387
|
|
